Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 2, 2003, Pages 267-274

  Villégier, Anne Sophie ^a   Blanc, Gérard ^a   Glowinski, Jacques ^a   Tassin, Jean Pol ^a  

^a l'alimentation et l'Environnement   (France)

Author keywords

Behavioral sensitization; Monoamine oxidases; Nicotine; Pargyline; Tranylcypromine

Indexed keywords

DEXAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; NICOTINE; PARGYLINE; SODIUM CHLORIDE; TOBACCO SMOKE; TRANYLCYPROMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; SMOKING CESSATION; WITHDRAWAL SYNDROME;

ANIMALIA; NICOTIANA TABACUM;

EID: 0142226998     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00223-5     Document Type: Article

References (48)

1. Auclair A., Cotecchia S., Glowinski J., Tassin J.P. D-Amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. J. Neurosci. 22:2002;9150-9154.
2. Balfour D.J., Wright A.E., Benwell M.E., Birrell C.E. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav. Brain. Res. 113:2000;73-83.
3. Berke J.D., Hyman S.E. Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 25:2000;515-532.
4. Berlin I., Said S., Spreux-Varoquaux O., Olivares R., Launay J.M., Puech A.J. Monoamine oxidase A and B activities in heavy smokers. Biol. Psychiatry. 38:1995;756-761.
5. Boye S.M., Grant R.J., Clarke P.B. Disruption of dopaminergic neurotransmission in nucleus accumbens core inhibits the locomotor stimulant effects of nicotine and D-amphetamine in rats. Neuropharmacology. 40:2001;792-805.
6. Breyer-Pfaff U., Wiatr G., Stevens I., Gaertner H.J., Mundle G., Mann K. Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking. Life Sci. 58:1996;1425-1432.
7. Cadoni C., Di Chiara G. Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur. J. Pharmacol. 387:2000;R23-R25.
8. Carr L.A., Basham J.K. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci. 48:1991;1173-1177.
9. Dani J.-A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 16:1996;905-908.
10. Darracq L., Blanc G., Glowinski J., Tassin J.P. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J. Neurosci. 18:1998;2729-2739.
11. Darracq L., Drouin C., Blanc G., Glowinski J., Tassin J.P. Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine. Neuroscience. 103:2001;395-403.
12. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 393:2000;295-314.
13. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5274-5278.
14. Drouin C., Blanc G., Villegier A.S., Glowinski J., Tassin J.P. Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. Synapse. 43:2002;51-61.
15. Erhardt S., Schwieler L., Engberg G. Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine. Synapse. 43:2002;227-237.
16. Ferrari R., Le Novere N., Picciotto M.R., Changeux J.P., Zoli M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur. J. Neurosci. 15:2002;1810-1818.
17. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R.et al. Inhibition of monoamine oxidase B in the brain of smokers. Nature. 379:1996;733-736.
18. Giorguieff-Chesselet M.F., Kemel M.L., Wandscheer D., Glowinski J. Regulation of dopamine release by presynaptic nicotine receptors in rat striatal slices: effect of nicotine in a low concentration. Life Sci. 25:1979;1257-1262.
19. Henry D.J., White F.J. The persistence of behavioral sensitization to cocaine parallels enhanced inhibition of nucleus accumbens neurons. J. Neurosci. 15:1995;6287-6299.
20. Johannessen J.N., Chiueh C.C., Bacon J.P., Garrick N.A., Burns R.S., Weise V.K.et al. Effects of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine in the dog: effect of pargyline pretreatment. J. Neurochem. 53:1989;582-589.
21. Ksir C., Hakan R., Hall D.P. Jr., Kellar K.J. Exposure to nicotine enhances the behavioral stimulant effect of nicotine and increases binding of [H3] acetylcholine to nicotine receptors. Neuropharmacology. 24:1985;527-531.
22. Louis M., Clarke P.B. Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology. 37:1998;1503-1513.
23. Lucas G., Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem. 74:2000;693-701.
24. Marchi M., Risso F., Viola C., Cavazzani P., Raiteri M. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem. 2002;1071-1078.
25. Marks M.J., Burch J.B., Collins A.C. Genetics of nicotine response in four inbred strains of mice. J. Pharmacol. Exp. Ther. 226:1983;291-302.
26. Miller D.K., Wilkins L.H., Bardo M.T., Crooks P.A., Dwoskin L.P. Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism. Psychopharmacology. 56:2001;469-476.
27. Mitchell S.N. Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine. Neuropharmacology. 32:1993;937-949.
28. Oreland L., Fowler C.J., Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci. 29:1981;2511-2518.
29. Pickworth W.B., Fant R.V., Nelson R.A., Rohrer M.S. Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine Tob. Res. 1:1999;357-364.
30. Pidoplichko V.I., DeBiasi M., Williams J.T., Dani J.A. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 390:1997;401-404.
31. Pierce J.P., Gilpin E.A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 288:2002;1260-1264.
32. Poindexter E.H., Carpenter R.D. The isolation of harmane and norharmane from tobacco and cigarette smoke. Phytochemistry. 1:1962;215-221.
33. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animals models of amphetamine psychosis. Brain Res. Rev. 11:1986;157-198.
34. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18:1993;247-291.
35. Robinson T.E., Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J. Neurosci. 17:1997;8491-8497.
36. Rommelspacher H., Meier-Henco M., Smolka M., Kloft C. The levels of norharman are high enough after smoking to affect monoamine oxidase B in platelets. Eur. J. Pharmacol. 441:2002;115-125.
37. Schoffelmeer A.N.M., de Vries T.J., Wardeh G., van de Ven H.W.M., Vanderschuren L.J.M.J. Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation. J. Neurosci. 22:2002;3269-3276.
38. Seth P., Cheeta S., Tucci S., File S.E. Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol. Biochem. Behav. 71:2002;795-805.
39. Sorenson E.M., Shiroyama T., Kitai S.T. Postsynaptic nicotinic receptors on dopaminergic neurons in the substantia nigra pars compacta of the rat. Neuroscience. 87:1998;659-673.
40. Tassin J.P., Stinus L., Simon H., Blanc G., Thierry A.M., Le Moal M.et al. Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of fronto-cortical DA innervation in the rat. Brain Res. 141:1978;267-281.
41. Tung C.S., Ugedo L., Grenhoff J., Engberg G., Svensson T.H. Peripheral induction of burst firing in locus coeruleus neurons by nicotine mediated via excitatory amino acids. Synapse. 4:1989;313-318.
42. Uebelhack R., Franke L., Schewe H.J. Inhibition of platelet MAOB by kava pyrone-enriched extract from Piper Methysticum Foster (kava-kava). Pharmacopsychiatry. 31:1998;187-192.
43. Vezina P., Blanc G., Glowinski J., Tassin J.P. Nicotine and morphine differentially activate brain dopamine in prefrontal and subcortical terminal fields: effects of acute and repeated injections. J. Pharmacol. Exp. Ther. 261:1992;484-490.
44. Vezina P., Herve D., Glowinski J., Tassin J.P. Injections of 6-hydroxydopamine into the ventral tegmental area destroy mesolimbic dopamine neurons but spare the locomotor activating effects of nicotine in the rat. Neurosci. Lett. 168:1994;111-114.
45. Wayment H.K., Schenk J.O., Sorg B.A. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J. Neurosci. 21:2001;35-44.
46. White F.J., Kalivas P.W. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend. 51:1998;141-153.
47. Yu P.H., Boulton A.A. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci. 41:1987;675-682.
48. Zhang W., Kilicarslan T., Tyndale R.F., Sellers E.M. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos. 29:2001;897-902.